Risankizumab is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials,” by Louis E, Schreiber S, Panaccione R, Bossuyt P, et al for the INSPIRE and COMMAND Study Group. JAMA. 2024 Jul 22:e2412414

Om Podcasten

A new monthly publication from the American College of Gastroenterology, Evidence-Based GI (EBGI) uses evidence-based methods to create abstracts and explain study results of new and important articles in the field of gastroenterology and hepatology. Listen as editors of EBGI discuss the articles they review and how the recommendations can be applied to your practice.